Patents Examined by Maher Haddad
  • Patent number: 9850303
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human TSPAN8 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome purification kits using the antibody.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 26, 2017
    Assignee: The Translational Genomics Research Institute
    Inventor: David Azorsa
  • Patent number: 9828422
    Abstract: An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 28, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Kyung Eun Kim, Seung Ja Oh, Hyo Seon Lee, Sang Yeul Han
  • Patent number: 9815900
    Abstract: The present invention relates to a novel monoclonal antibody which is specifically bound to a transmembrane 4 L six family member 5 (TM4SF5) protein. More particularly, the present invention relates to a monoclonal antibody which is specifically bound to a human TM4SF5 protein, to polynucleotides coding for the monoclonal antibody, to an expression vector comprising the nucleotides, to a transformant with the vector introduced thereto, to a method for preparing the monoclonal antibody, to a composition comprising the monoclonal antibody, to a method for treating liver fibrosis using the monoclonal antibody, to a method for treating cancer using the monoclonal antibody, to a method for inhibiting metastasis of cancer, to a method for diagnosing cancer using the monoclonal antibody and to a cancer diagnosis kit comprising the monoclonal antibody.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: November 14, 2017
    Assignees: Korea Research Institute of Bioscience and Biotechnology, SNU R&DB Foundation
    Inventors: Se Mi Kim, Sang Jick Kim, Hye Jin Min, Jin Myeong Song, Jung Weon Lee, Hye Jin Kim, HyeMi Ahn, InPyo Choi, JiHye Ryu
  • Patent number: 9808522
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: November 7, 2017
    Assignees: UNIVERSITATSKLINIKUM FREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • Patent number: 9777276
    Abstract: The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the ablation of ADAM12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: October 3, 2017
    Assignee: INSTITUT PASTEUR
    Inventors: Lucie Peduto, Gerard Eberl
  • Patent number: 9777060
    Abstract: The present invention relates to a novel antibody specifically binding to human and mouse L1CAM, and more particularly, to an antibody binding to both human and mouse L1CAM with high affinity, which is prepared by modifying a sequence of an L1 cell adhesion molecule (L1CAM)-specific antibody comprising a heavy-chain variable region of SEQ ID NO. 1 and a light-chain variable region of SEQ ID NO. 5, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide, a transformant introduced with the vector, a pharmaceutical composition for preventing or treating cancer comprising the antibody, a method for treating cancer using the antibody, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for providing information for cancer diagnosis using the antibody, and an antibody-drug conjugate prepared by conjugating a drug to the antibody.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: October 3, 2017
    Assignees: KANGWON NATIONAL UNIVERSITY University-Industry Cooperation Foundation, Korea Research Insititute of Bioscience and Biotechnology
    Inventors: Hyo Jeong Hong, In Soo Park, Seul Ki Cho, Mun Sik Jeong, Singh Rohit
  • Patent number: 9777055
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: October 3, 2017
    Assignee: Thomas Jefferson University
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • Patent number: 9751933
    Abstract: Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clec14a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clec14a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clec14a as an epitope for an antibody suppressive of angiogenesis.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: September 5, 2017
    Assignee: SCRIPPS KOREA ANTIBODY INSTITUTE
    Inventors: Suk Mook Lee, Min kyoung Ki, Mee Hyun Jeoung, Jong Rip Choi
  • Patent number: 9745376
    Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: August 29, 2017
    Assignees: Biogen MA Inc., The Regents of the University of California
    Inventors: Shelia M. Violette, Paul Henry Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
  • Patent number: 9701744
    Abstract: An anti-Vasohibin-2 antibody, a genetically recombinant anti-Vasohibin-2 antibody, or a fragment thereof, which recognizes amino acid numbers 269 to 288 of the amino acid sequence shown in SEQ ID NO: 2. The anti-Vasohibin-2 antibody of the present invention recognizes a Vasohibin-2 protein with an excellent specificity, and can inhibits an action of promoting angiogenesis owned by the Vasohibin-2 protein, so that the pharmaceutical composition containing the anti-Vasohibin-2 antibody is suitably used in the treatment of a disease requiring inhibition of angiogenesis such as cancer, and the like.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: July 11, 2017
    Assignee: TOHOKU UNIVERSITY
    Inventor: Yasufumi Sato
  • Patent number: 9695241
    Abstract: The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: July 4, 2017
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Jianghuai Xu
  • Patent number: 9688732
    Abstract: Isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: June 27, 2017
    Assignees: MOR—RESEARCH APPLICATIONS LTD., RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
    Inventors: Michal A. Rahat, Nitza Lahat, Miriam Walter, Haim Bitterman
  • Patent number: 9688746
    Abstract: The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: June 27, 2017
    Assignee: Canimguide Therapeutics AB
    Inventors: Leif HÃ¥kansson, Birgitta Clinchy
  • Patent number: 9683040
    Abstract: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenesis effect in in-vivo models.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: June 20, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshitaka Isumi, Toshiyuki Sato, Jun Hasegawa, Tatsuya Inoue
  • Patent number: 9663579
    Abstract: Methods for achieving clinical response of Crohn's disease in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: May 30, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Irving H. Fox, Catherine Scholz
  • Patent number: 9662373
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: May 30, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Alexander T. Kozhich, Martin J. Corbett
  • Patent number: 9644030
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: May 9, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Ellen A. Garber Stark, Jose William Saldanha
  • Patent number: 9631029
    Abstract: The present invention relates to an antibody, recombinant or synthetic antigen-binding fragments thereof able to recognize and bind an epitope comprised in the spacer domain of ADAMTS-5, nucleic acid and expression vector encoding the same, method of production and uses thereof.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: April 25, 2017
    Assignee: ROTTAPHARM BIOTECH S.R.L.
    Inventors: Riccardo Chiusaroli, Michela Visintin, Gianfranco Caselli, Lucio Claudio Rovati
  • Patent number: 9605057
    Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: March 28, 2017
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Philipp Erich Scherer, Jiyoung Park, Zhiqiang An
  • Patent number: 9605083
    Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: March 28, 2017
    Assignee: Emory University
    Inventors: Charles A. Parkos, Dominique A. Weber